|
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Eviti; Janssen; Medivation/Astellas |
Research Funding - Myriad Genetics |
Other Relationship - Caribou Publishing |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen |
Research Funding - Astellas Pharma (Inst); Janssen (Inst) |
|
|
Stock and Other Ownership Interests - CORE Science Solutions |
Honoraria - Amgen; Dompé Farmaceutici; Foundation Medicine |
Consulting or Advisory Role - Amgen; Dompé Farmaceutici; Foundation Medicine |
|
|
Consulting or Advisory Role - ViewRay |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer |
Research Funding - Dendreon (Inst); Genomic Health (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Seagen |
|
|
Research Funding - Janssen (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - GlaxoSmithKline; Janssen; Janssen; Novartis; Pfizer; Sanofi |
Travel, Accommodations, Expenses - Novartis |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen |
|
|
Research Funding - Dendreon (Inst); Prometheus (Inst) |
Patents, Royalties, Other Intellectual Property - No company |
Travel, Accommodations, Expenses - Prometheus |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Pfizer |